Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30 participants
OBSERVATIONAL
2018-02-01
2019-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Accuracy of Corneal Astigmatism in Different Region Modes
NCT03299530
A Comprehensive Assessment of Anterior Corneal Power by Different Devices
NCT01587287
Changes in Amblyopia Using Optical Coherence Tomography
NCT04092361
Prospective Clinical Study of Retinal Microvascular Alteration After ICL Implantation
NCT04443231
Effectiveness and Safety of Limbal Relaxing Incisions for Correcting Post Phacoemulsification High Astigmatism
NCT06896357
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
High myopia is one of the most prevalent refractive condition globally with a higher risk of other eye conditions Moreover in high myopic eyes the incidence of cataract is significantly higher than in non myopic eyes and the progression is also faster.
Calculation of IOL in high myopic eyes remains a challenge often leading to unexpected postoperative hyperopia the main potential sources of errors in IOL calculation for high myopic eyes include AL measurement \& IOL constants used \&IOL power calculation formula used.
investigators suspect that the SRK I1 formula is inaccurate for myopic eyes, and that new formulas are needed, taking into account all those factors that make up the dioptric power of an eye.
Formulas for IOL power calculation had past four generations, first generation formulas were theoretical and based on the same fundamental constant with no respect to anterior chamber depth. Since then, Binkhorst, Holladay, Hoffer and Shammas had refined the existing theoretical formulas where each of them developed his regression formula based on analysis of their previous IOL cases .
This work was amalgamated in 1980 and yielded the Sanders Retzlaff Kraff I (SRKI) formula The second generation was designed by combining linear regression analysis and stepwise adjustment for long and short eyes according to anterior chamber depth .
The third and fourth generation formulas, started by Holladay in 1988, all aimed at better calculation of the IOL power in eyes with extreme axial length where another term had appeared which is IOL specific anterior chamber depth .
The accuracy of third and fourth generation formulas for IOL calculation in patients with high axial myopia had not been fully evaluated For that, the need for more studies conducted to evaluate such accuracy is crucial.
This study will be conducted to evaluate the accuracy of different formulas used for IOL power calculation in patients with high axial myopia undergoing cataract surgery
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CROSSOVER
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
iol power calculation
iol power calculation in high myopia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2-their IOLpower is less than 15 diopter or their refraction before operation is more than -6.
Exclusion Criteria
2. Patients with post operative complications like posterior capsule injury or vitrous loss.
3. patients who had undergone previous intraocular surgery at anterior segment or posterior segment.
30 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
salma safwat abdelhady mangora
ophthalmology resident
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
29110202500209
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.